

ASX & Media Release

## Patrys Adds Two New Products to Pipeline

- **PAT-SM4 and PAT-SM5 elevated to product pipeline and advanced development**
- **Both products show potent anti-cancer properties in a broad panel of experiments**
- **Further evidence of ability to consistently expand product pipeline**
- **Remaining library of over 200 natural human antibodies support a robust future**

**Melbourne, Australia; 18 June, 2010:** Patrys Limited (ASX: PAB), a biopharmaceutical company focused on the development of natural human antibody based therapies for deadly cancers, announced today that it has elevated two new products to its pipeline, PAT-SM4 and PAT-SM5.

The Company has now added three new products to its pipeline during CY2010, exceeding the previously stated goal of two new products per year. Each new product offers significant potential with strong anti-cancer activity demonstrated in pre-clinical testing.

PAT-SM4 has been shown to bind to 97% of 91 different tumours obtained from patients with a variety of cancers including gastric, pancreatic, lung, breast and prostate cancers. PAT-SM4 has also been shown to be effective at reducing proliferation on a variety of cancer cell types, including pancreatic, colon and lung cancer cells.

PAT-SM5 has been shown to bind to 79% of 89 different tumours obtained from patients with a variety of cancers including pancreatic, lung, breast and ovarian cancers. Similar to PAT-SM4, PAT-SM5 has also been shown to be effective in laboratory experiments at inhibiting proliferation of pancreatic, colon and lung cancer cells.

Both PAT-SM4 and PAT-SM5 will now be advanced into animal experiments to further define their respective anti-cancer activities and to help identify the most appropriate cancers to target for future clinical trials. The Company's R&D unit will also identify the target for each antibody, which is the protein on the surface of cancer cells against which the products are directed.

The Company's pipeline now includes 13 products.

The most advanced of Patrys' products, PAT-SC1, has already been evaluated in a Phase I/II human clinical trial where it significantly extended the survival of treated gastric cancer patients versus a non-treated historical control group. A larger gastric cancer clinical trial is planned for CY2011. Gastric cancer is one of the most common cancers in the world. Stomach cancer is the 10<sup>th</sup> most common cancer in Australia mainly due to a large migrant population. The incidence of stomach cancer in developed countries is decreasing due to improved diet and diagnosis.

A first in-human clinical trial for PAT-SM6, another promising internal product, is expected to commence in the next 30 to 60 days and will be focused on treating melanoma patients. Melanoma is a very serious global concern, with an expected doubling of incidence every 10 to 20 years. Melanoma has a disproportionately negative impact, as Australians are much more likely to be diagnosed with melanoma relative to other industrialised nations due to increased sun exposure.

Of the remaining products in Patrys' pipeline, five are the subject of commercial agreements with larger industry partners including CSL Limited.

Patrys CEO, Dan Devine, commented: "Our strategy is to mature as quickly as possible by advancing several products through human clinical trials as internal programs and partnering additional products with larger companies. This approach offers multiple and diverse opportunities for value creation while at the same time lowering the need to develop all of our products using internal resources."

"This strategy is dependent on generating new products on a continual basis, and our R&D team has proved that it can do this effectively. So while we already have multiple internal products at the clinical development stage, and also many products subject to existing commercial transactions, we can continue to add new internal and partnering opportunities in an ongoing manner."

Patent applications have been filed to cover PAT-SM4 and PAT-SM5. A patent application was also recently filed to cover PAT-SM3, which was elevated to Patrys' pipeline in March of this year.

**-Ends-**

**For further information, please contact:**

Patrys Limited:

Daniel Devine  
Chief Executive Officer  
P: +61 3 9670 3273  
[info@patrys.com](mailto:info@patrys.com)

Patrys Media and Investors:

Rebecca Wilson  
Buchan Consulting  
P: +61 4 1738 2391  
[rwilson@bcg.com.au](mailto:rwilson@bcg.com.au)

**About Patrys Limited:**

Based in Melbourne, Australia, Patrys (ASX: PAB) is focused on the development of natural human antibody therapies for cancer. Patrys has a pipeline of six internal lead candidates and five additional lead products that are the subject of collaboration agreements with larger industry partners. More information can be found at [www.patrys.com](http://www.patrys.com).

**About PAT-SC1:**

PAT-SC1 is a natural human antibody that acts by binding to a special form of a protein, called CD55 that appears on the surface of gastric cancer cells but not on the surface of healthy cells, thereby permitting PAT-SC1 to kill the cancer cells while sparing the healthy cells. PAT-SC1 was evaluated in an investigator led human clinical trial, under which treated patients were dosed with PAT-SC1 48 hours prior to a surgical procedure that involved the removal of the primary tumour (surgical removal of the tumour is currently the standard treatment). Thirty-five PAT-SC1 treated gastric cancer patients showed a statistically significant increased survival benefit compared to a historic control group of 53 patients that received the same surgical treatment but who did not receive PAT-SC1. Additional published data shows that PAT-SC1 at this dose level was very safe and well tolerated by patients receiving the treatment. The referenced clinical results were compiled by an independent research firm.

**About PAT-SM6:**

The natural human antibody PAT-SM6 has been shown to have potent anti-cancer properties in a large number of laboratory and animal studies. In addition, Patrys has now screened PAT-SM6 against more than 200 tumours from individual patients with various cancers, and the product binds to over 90% of the tumours screened regardless of cancer type, age, gender or disease stage. With respect to melanoma, PAT-SM6 has shown particularly strong promise. In a broad panel of experiments, PAT-SM6 has shown a potent ability to kill melanoma cells. In addition, PAT-SM6 has been shown to bind to 100% of different malignant melanoma patient tumours screened, an attribute that not only opens up commercial opportunities, but also greatly facilitates clinical development because all patients can be included in the respective clinical trials. Patrys has filed patent applications to cover the PAT-SM6 antibody molecule, disease target, and mechanism of action.